

THE LANCET

Infectious Diseases

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Bager P, Wohlfahrt J, Rasmussen M, Albertsen M, Krause TG. Hospitalisation associated with SARS-CoV-2 delta variant in Denmark. *Lancet Infect Dis* 2021; published online Sept 3. [http://dx.doi.org/10.1016/S1473-3099\(21\)00580-6](http://dx.doi.org/10.1016/S1473-3099(21)00580-6).

Appendix to

Article type: Correspondence

Title: Hospitalisation associated with SARS-CoV-2 delta variant in Denmark

Authors: Peter Bager¹, PhD, Jan Wohlfahrt², DMSc, Morten Rasmussen³, PhD, Mads Albertsen⁴, PhD, Tyra Grove Krause¹, PhD.

¹Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark

²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

³Department of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark

⁴Department of Chemistry and Bioscience, Aalborg University, Denmark

Table. Infection with lineage B.1.1.7 (alpha) and B.1.617.2 (delta) and other lineages and risk of hospitalisation overall and by age and vaccination, among 88,858 cases between 1 January and 11 July, 2021, Denmark.

					COVID-19 hospitalisation*			
	Yes (n=4014)		No (n=84844)		Crude	p value	Adjusted	p value
Infection with SARS-CoV-2 lineages						P<0.0001		P<0.0001
No (other lineages)	1460	(6.6)	20709	(93.4)	1.73 (1.63-1.85)	-	0.75 (0.67-0.83)	-
B.1.1.7	2510	(3.8)	63543	(96.2)	1 (ref)	-	1 (ref)	-
B.1.617.2	44	(6.9)	592	(93.1)	1.82 (1.37-2.43)	-	2.83 (2.02-3.98)	-
B.1.617.2 by age (reference in B.1.1.7)						P=0.24		P=0.46
0-29	10	(3.1)	311	(96.9)	3.26 (1.76-6.06)	-	3.58 (1.84-6.98)	-
30-59	27	(9.5)	256	(90.5)	1.89 (1.31-2.71)	-	2.97 (1.98-4.46)	-
60+	7	(21.9)	25	(78.1)	1.39 (0.72-2.68)	-	2.03 (1.01-4.08)	-
B.1.617.2 by vaccination status at infection (reference in B.1.1.7)						P=0.045		P=0.14
Not vaccinated	30	(6.9)	404	(93.1)	2.37 (1.67-3.36)	-	3.01 (2.02-4.50)	-
Positive before or <=14 days after 1st vaccination	10	(9.3)	97	(90.7)	1.72 (0.95-3.11)	-	3.98 (2.27-6.99)	-
Positive >14 days after 1st vaccination (excl. below)	2	(2.7)	71	(97.3)	0.64 (0.16-2.56)	-	1.29 (0.30-5.48)	-
Positive >14 days after 2nd vaccination	2	(9.1)	20	(90.9)	0.91 (0.24-3.50)	-	1.25 (0.34-4.59)	-

Data are n (%) or risk ratio (RR) (95% CI). p values in the stratified analysis are tests for interaction terms. Adjusted RRs were adjusted for the basic (a priori) covariates sex, age (10-year groups), sample period (calendar week), region (five groups), comorbidities in the preceding 5 years (none or one or more), as well as vaccination (grouped as shown). RRs in the stratified analysis were adjusted for the remaining basic covariates. However, in strata by age (three age-groups), RR were also adjusted for age in 10-year groups. Restricting to the period since the first delta case on April 2, the RR for B.1.617.2 was 2.86 (2.03-4.03) (reference in B.1.1.7). * A Covid-19-related hospital admission was defined as any new admission occurring between 2 days before until 14 days after a positive SARS-CoV-2 PCR test and lasting 12 hours or more. All cases had at least 14 days of follow-up after the test date.